NASDAQ$AQST
Aquestive Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third quarter and provided a business update.
Aquestive Therapeutics reported a 4% increase in total revenues to $13.5 million for the third quarter of 2024, driven by increases in license and royalty revenue, offset by decreases in manufacture and supply revenue. The company is advancing its key product candidates, Anaphylm and AQST-108, with pre-NDA and pre-IND meetings scheduled for the fourth quarter of 2024, respectively. Aquestive finished the quarter with approximately $78 million in cash and reaffirms its cash runway into 2026.
- Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024
- AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024
- Libervant® (diazepam) Buccal Film for patients aged 2-5 available through retail distribution channels
- Finished third quarter 2024 with approximately $78 million of cash and reaffirms cash runway into 2026
Headline financials
Revenue & EPS history
Aquestive · Revenue · Quarterly
$13.5M
Forward guidance
Aquestive expects total revenue between $57 million and $60 million and a non-GAAP adjusted EBITDA loss between $20 million and $23 million for the full year 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-0.4%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+8.5%
Avg return
30 days after
45%
14 / 31 earnings
Positive
+22.8%
Q3 2019
Best reaction
-44.2%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.2% | -1.0% | +0.0% | |
| Q4 2025 | -2.5% | -3.9% | -5.5% | |
| Q3 2025 | +2.0% | -5.2% | +6.3% | |
| Q1 2025 | -19.4% | -16.5% | +16.1% | |
| Q4 2024 | -7.5% | -5.4% | -2.9% | |
| Q3 2024 | -13.8% | -1.1% | -21.9% | |
| Q2 2024 | +4.3% | +4.3% | +28.6% | |
| Q1 2024 | -11.7% | -11.7% | -19.7% | |
| Q4 2023 | +20.3% | +16.7% | -0.5% | |
| Q3 2023 | +6.9% | +5.0% | +28.7% | |
| Q2 2023 | -7.2% | -7.2% | -24.4% | |
| Q1 2023 | +20.9% | +46.8% | +66.2% | |
| Q4 2022 | +5.6% | -1.4% | +45.3% | |
| Q3 2022 | -3.4% | +0.6% | +7.5% | |
| Q2 2022 | -2.2% | +2.7% | +50.5% | |
| Q1 2022 | +0.7% | -14.2% | -32.6% | |
| Q4 2021 | -4.8% | -12.6% | -18.0% | |
| Q3 2021 | +12.6% | +10.7% | +2.7% | |
| Q2 2021 | +11.2% | +12.1% | +39.6% | |
| Q1 2021 | -3.3% | -14.1% | -6.8% | |
| Q4 2020 | +11.5% | +24.6% | +11.5% | |
| Q3 2020 | +3.6% | +4.9% | +29.6% | |
| Q2 2020 | +4.0% | +10.5% | +26.5% | |
| Q1 2020 | -4.0% | +14.4% | +14.2% | |
| Q4 2019 | -44.2% | -55.2% | -16.0% | |
| Q3 2019 | +22.8% | +26.8% | +95.8% | |
| Q2 2019 | +12.5% | +22.7% | +14.1% | |
| Q1 2019 | -11.4% | -14.9% | -29.9% | |
| Q4 2018 | -14.4% | -8.3% | -18.7% | |
| Q3 2018 | -1.1% | -7.8% | -15.1% | |
| Q2 2018 | -0.3% | +5.3% | -7.7% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro